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The duration of hepatitis B vaccine-induced immunity was studied in a group of 54
seronegative health professionals who received plasma-derived hepatitis B vaccine (Merck's
Heptavax) in 1978 and 1979. Five to seven years later, 52 vaccinees received a booster dose of
yeast recombinant hepatitis B vaccine (Merck's Recombivaxs). Of54 vaccinees, 47 (87 percent)
had a favorable anti-HBs reponse (>10 S/N RIA units) and 7 (13 percent) had low (2.1-10
S/N) or undetectable levels (<2.1 S/N) one yearafter primary immunization. After fivetoseven
years, theanti-HBsvalues had declined toundetectable levels in 25 percent and tolow levels in 23
percent. A booster dose ofvaccine induced an anamnestic response in 90 percent ofvaccinees by
two weeks. The results of this study indicate that persons who respond favorably to primary
immunization may be protected for at least seven years.
INTRODUCTION
The first inoculations of inactivated hepatitis B vaccine were administered to 11
adult volunteers in November 1975. Sincethat time many millions ofinfants, children,
and adults worldwide have been immunized with various plasma-derived vaccines.
Experience during the past ten years has confirmed the safety, immunogenicity, and
efficacy ofthese vaccines [1-4].
Thedevelopment ofan inactivated hepatitis Bvaccine andits licensurein theUnited
States in November 1981 was an important milestone in the history of preventive
medicine. The technology that led to the development of the vaccine also led to the
development ofspecific, sensitive tests for thedetection ofmarkers for hepatitis Bvirus
(HBV) infection. Seroepidemiological surveys by many investigators confirmed that
hepatitis B was a major public health problem in most countries ofthe world.
The seroepidemiological surveys have revealed that about 200 million persons
worldwide are asymptomatic HBV carriers. In addition, HBV-related hepatoma is the
most common malignant tumor in many Asian and African countries, accounting for
20 to 40 percent ofall cancer deaths among men in these areas. In contrast, hepatoma
is responsible for only 2 percent ofmalignant tumors in the United States.
Although hepatitis is less prevalent in the United States, its toll is still significant.
The Centers for Disease Control has estimated that about 200,000 HBV infections
occur each year. Of these, about 50,000 persons have clinically recognizable disease
with jaundice, about 10,000 may require hospitalization, and about 10,000 to 20,000
will become chronic HBV carriers. In addition, about 40,000 persons will die of
HBV-related cirrhosis and about 800 deaths will be caused by HBV-related cancer of
the liver. These impressive statistics highlight the need for an effective hepatitis B
vaccine.
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DEVELOPMENT OF HEPATITIS B VACCINE
Plasma-Derived Vaccines
The chronological events that led to thedevelopment ofhepatitis Bvaccine began in
1965 with the report of the discovery of the Australia antigen by Blumberg et al. [5]
and its subsequent association with hepatitis B by Prince [6] and by Giles et al. [7]. In
1970 Dane et al. [8] identified by immune electron microscopy 42 nm double-shelled,
virus-like particles in theserumofpatients with Australia antigen-associated hepatitis.
Later, it became apparent that the "Dane particle" was the hepatitis B virion. It also
became apparent that Australia antigen was immunologically identical with the
surface component of HBV and with the 20 nm particles present; it was immunologi-
cally distinct from the core component of HBV. Therefore, Australia antigen was
designated as hepatitis B surface antigen (HBsAg), and the core component was
designated as hepatitis B core antigen (HBcAg).
In 1970 Krugman et al. demonstrated that the inactivated HBV serum (MS-2
strain), which contained large quantities of HBsAg as well as the virus, was not
infectious but it was antigenic [9]. The detection ofantibody to HBsAg (anti-HBs) in
the serum of recipients of the heat-inactivated MS-2 serum indicated that the
non-infectious HBsAg particle was the antigen needed for vaccine production. In
subsequent studies we demonstrated that heat-inactivated MS-2 serum was immuno-
genic and partially protective [10].
Vaccine development was accelerated in 1972 and 1973 when hepatitis B was
successfully transmitted to non-human primates [11]. Seronegative chimpanzees
proved to be excellent animal models for the study of HBV infection and for the
safety-testing of hepatitis B vaccines. In addition, the development ofsensitive assays
to detect markers of HBV infection (HBsAg, anti-HBs, anti-HBc [hepatitis B core
antibody], HBeAg [hepatitis B e antigen], and anti-HBe [antibody to HBeAg])
provided reliable indicators ofvaccine safety and immunogenicity. By the mid-1970s
several investigators had prepared inactivated hepatitis B vaccines from purified
preparations ofHBsAg [12,13]. The source ofthe antigen was HBsAg-positive plasma
from chronic carriers.
The preparation ofthe plasma-derived vaccine that is manufactured and licensed in
the United States involves a series of complex physical and chemical procedures to
isolate the 20 nm spherical HBsAg particles. These procedures include three separate
inactivation steps: pepsin at pH2, 8 M urea, and a 1:4,000 dilution offormalin. Each of
these steps has been shown to inactivate the following viruses that may be present in
blood: HBV; non-A, non-B hepatitis virus; herpesviruses; and human immunodefi-
ciency virus (HIV).
Recombinant Hepatitis B Vaccine
The use of DNA recombinant technology has enabled investigators to synthesize
HBsAg in cells of baker's yeast, Saccharomyces cervisiae. The final purified HBsAg
particles have close structural and biochemical similarities to particles derived from
plasma ofchronic HBsAg-positive carriers [14]. Studies by various investigators have
confirmed the safety, immunogenicity, and efficacy ofthe yeast recombinant hepatitis
B vaccine prepared by Merck, Sharp and Dohme [15].
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Studies ofVaccine-Induced Immunity
Theduration ofvaccine-induced immunity was studied in a groupof54 seronegative
health professionals in 1978 and 1979. Initially they received 20 ,ug doses of Merck
plasma-derived vaccine at zero, one, two, and nine months. Subsequently serum
specimens were obtained one year and five to seven years after primary immunization.
The sera were tested for anti-HBs by solid radioimmunoassay (Ausab; Abbott
Laboratories, North Chicago, IL). The anti-HBs test results were calculated as the
ratioofsample counts per minute (cpm) to the mean negativecontrol cpm (S/N), with
values of >2.1 considered positive.
A 10 Mg booster dose of yeast recombinant vaccine was given to 52 of the 54
vaccinees five to seven years after the initial immunization. The results of serial tests
for anti-HBs one year after the primary immunization and 2, 4, and 26 weeks after the
booster dose are shown in Table 1. Two vaccinees (numbers 53 and 54) did not receive
a booster dose because they contracted hepatitis B with jaundice five years after the
initial immunization.
A review ofthe data listed in Table 1 reveals the following findings:
1. Of 54 vaccinees, 47 (87 percent) had a favorable antibody response (10-477
S/N) one year after primary vaccination, 4 (8 percent) had low levels of anti-HBs
(2.1-10 S/N), and 3 (5 percent) had no detectable anti-HBs (<2.1 S/N).
2. The anti-HBs status of 52 vaccinees five to seven years after the primary
immunization was as follows: 13 (25 percent) had no detectable antibody; 12 (23
percent) had low levels (2.1-10 S/N) and 27 (52 percent) had favorable levels (>10
S/N).
3. After the booster dose ofvaccine an anamnestic response at two to four weeks
was detected in 47 (90 percent) of the vaccinees. There were five poor or non-
responders (numbers 3, 7, 9, 11, and 12).
4. The two vaccinees who contracted hepatitis B five years after primary
immunization were poor (number 53) or non-responders (number 54).
The induction ofan anamnestic response five to seven years after successful primary
immunization was very encouraging. High levels of antibody by two weeks were
observed in most vaccinees who had low or undetectable levels of anti-HBs before
receiving the booster dose. This finding is reassuring because the incubation period of
hepatitis B usually exceeds six weeks. Therefore, immunologically primed vaccinees
should be protected following exposure to HBV. The induction of an anamnestic
response during the early phase of the incubation period should prevent or modify
hepatitis B infection. In addition, this type ofasymptomatic HBV infection should be
followed by lasting immunity.
Long-term follow-up studies by Stevens et al. [16] revealed evidence ofa prolonged
protective effect of hepatitis B vaccine in high-risk homosexual men who participated
in their efficacy trial. Of 455 men who received plasma-derived vaccine at zero, one,
and six months, 444 (97.5 percent) had an anti-HBs response and 11 (2.5 percent)
were non-responders. During the four- to five-year follow-up period, 28 hepatitis B
infections occurred among the 455 men. Of the 28 infections, 25 (89 percent) were
inapparent. These inapparent infections were characterized by absence of symptoms,
normal ALTvalues, nodetectable HBsAg, a boost in anti-HBsvalues, and seroconver-
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TABLE 1
Anti-HBs Response Following Primary Immunization with Plasma-Derived Hepatitis B Vaccine and a
Subsequent Booster Dose of Yeast Recombinant Hepatitis B Vaccine Five to Seven Years Later
(Results are recorded as RIA ratio units [S/N].)
anti-HBs Response S/N
Years after Primary Immunization
Sex I
M 69
F 72
F 3
M 26
M 27
M 70
M 6
F 13
M <2.1
F 10
M <2.1
M 23
M 93
M 34
M 27
M 103
M 24
M 253
M 40
F 160
F 73
F 69
F 99
M 145
F 477
F 99
F 214
M 60
F 144
F 214
F 166
F 205
F 100
M 41
F 64
F 88
F 217
M 206
M 385
M 266
M 10
F 128
M 274
M 8
M 125
F 43
M 168
5 6
<2.1
- 2.8
3
13
22
29
36
7
<2.1
<2.1
<2.1
<2.1
<2.1
<2.1
<2.1
<2.1
<2.1
<2.1
<2.1
<2.1
2.3
2.6
3
4
4
6
6
9
9
11
12
12
13
15
16
17
18
20
36
38
41
42
49
75
66
87
144
192
2
101
22
5
165
22
19
5
30
3
19
<2.
<2.
82
226
165
60
142
40
179
225
220
133
157
192
124
219
147
205
177
201
288
168
146
192
147
154
159
195
14
106
137
118
112
141
190
Weeks after Booster
4
101
12
6
115
16
23
7
44
<2.1
45
.1 <2.1
.1 <2.1
95
165 1
139
78
37
140
28
179 1
158 1
227 1
140
99 11
183
193 1
196 21
145 1'
250 H
238 1
136
209
145 1
157 1
173 21
224 14
187 1:
151 1!
145
144
96
83
184
120
218
219 1
293
26
24
<2.1
<2.1
88
<2.1
5
3
13
<2.1
6
<2.1
41
36
40
11
7
8
37
55
15
93
07
93
12
!03
92
03
54
63
04
76
!01
49
22
90
95
12
15
49
44
38
67
No. Age
1 51
2 45
3 37
4 36
5 28
6 41
7 45
8 43
9 37
10 41
11 46
12 74
13 47
14 54
15 36
16 44
17 59
18 40
19 39
20 64
21 46
22 30
23 34
24 49
25 41
26 34
27 35
28 38
29 45
30 74
31 28
32 49
33 43
34 33
35 31
36 34
37 40
38 34
39 38
40 35
41 41
42 52
43 38
44 34
45 30
46 42
47 35
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TABLE 1-continued
anti-HBs Response S/N
Years after Primary Immunization Weeks after Booster
No. Age Sex 1 5 6 7 2 4 26
48 33 F 217 66 147 187 122
49 28 F 219 99 220 170 150
50 28 F 28 3.4 112 153 168
51 34 M 101 29 138 98 62
52 34 M 204 112 - 173 160 156
53 30 M 6 <2.1 Hepatitis B at 5 years (No booster)
54 39 M <2.1 <2.1 Hepatitis B at 5 years (No booster)
-, Not tested
sion of anti-HBc from negative to positive. The 25 inapparent infections occurred in
men who had detectable as well as undetectable anti-HBs.
Three apparent hepatitis B infections occurred among the 11 men who did not
respond to three doses of vaccine. These infections were characterized by abnormal
ALT values, detection of HBsAg, a boost in anti-HBs values, seroconversion of
anti-HBc from negative to positive, and presence of a chronic HBsAg carrier state in
one man.
The results of the present study and the study by Stevens et al. [16] indicate that
successfully immunized persons may be protected for as long as seven years after
primary immunization with inactivated hepatitis B vaccine. It is likely that persons
who respond to primary immunization will have long-lasting immunity.
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